Implications of Probiotics on the Maternal-Neonatal Interface: Gut Microbiota, Immunomodulation, and Autoimmunity

Simple item page
dc.contributor.authorSwartwout, Brianna K.en
dc.contributor.authorLuo, Xin M.en
dc.date.accessioned2019-01-18T19:04:15Zen
dc.date.available2019-01-18T19:04:15Zen
dc.date.issued2018-12-03en
dc.description.abstractProbiotics are being investigated for the treatment of autoimmune disease by re-balancing dysbiosis induced changes in the immune system. Pregnancy is a health concern surrounding autoimmune disease, both for the mother and her child. Probiotics for maternity are emerging on the market and have gained significant momentum in the literature. Thus far, evidence supports that probiotics alter the structure of the normal microbiota and the microbiota changes significantly during pregnancy. The interaction between probiotics-induced changes and normal changes during pregnancy is poorly understood. Furthermore, there is emerging evidence that the maternal gut microbiota influences the microbiota of offspring, leading to questions on how maternal probiotics may influence the health of neonates. Underpinning the development and balance of the immune system, the microbiota, especially that of the gut, is significantly important, and dysbiosis is an agent of immune dysregulation and autoimmunity. However, few studies exist on the implications of maternal probiotics for the outcome of pregnancy in autoimmune disease. Is it helpful or harmful for mother with autoimmune disease to take probiotics, and would this be protective or pathogenic for her child? Controversy surrounds whether probiotics administered maternally or during infancy are healthful for allergic disease, and their use for autoimmunity is relatively unexplored. This review aims to discuss the use of maternal probiotics in health and autoimmune disease and to investigate their immunomodulatory properties.en
dc.description.sponsorshipPreparation of this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number 1R01AR073240 and 1R15AR067418. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.en
dc.format.extent14 pagesen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationSwartwout B and Luo XM (2018) Implications of Probiotics on the Maternal-Neonatal Interface: Gut Microbiota, Immunomodulation, and Autoimmunity. Front. Immunol. 9:2840. doi: 10.3389/fimmu.2018.02840en
dc.identifier.doihttps://doi.org/10.3389/fimmu.2018.02840en
dc.identifier.urihttp://hdl.handle.net/10919/86773en
dc.identifier.volume9en
dc.language.isoen_USen
dc.publisherFrontiersen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectprobioticsen
dc.subjectgut microbiotaen
dc.subjectmaternalen
dc.subjectneonatalen
dc.subjectautoimmunityen
dc.titleImplications of Probiotics on the Maternal-Neonatal Interface: Gut Microbiota, Immunomodulation, and Autoimmunityen
dc.title.serialFrontiers in Immunologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fimmu-09-02840.pdf
Size:
1.07 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Open Access Subvention Fund Articles
Scholarly Works, Fralin Biomedical Research Institute at VTC